EyePoint Pharmaceuticals appointed Jay Duker, MD, to serve as the company's chief strategic scientific officer.
What you should know:
1. The ophthalmology pharmaceutical company created the role for Dr. Duker.
2. Dr. Duker will lead the strategic advancement of research and development efforts, while continuing his practice at Boston-based Tufts Medical Center.
3. He'll initially focus on EYP-1901, a wet age-related macular degeneration treatment candidate.
EyePoint President and CEO Nancy Lurker said, "We are delighted to have Jay join our executive team as our Chief Strategic Scientific Officer bringing his world class experience as a retinal specialist to EYP-1901."